Quote | Surrozen Inc. (NASDAQ:SRZN)
Last: | $10.9899 |
---|---|
Change Percent: | 4.4% |
Open: | $9.77 |
Close: | $10.9899 |
High: | $10.9899 |
Low: | $9.55 |
Volume: | 4,138 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Surrozen Inc. (NASDAQ:SRZN)
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...
Message Board Posts | Surrozen Inc. (NASDAQ:SRZN)
Subject | By | Source | When |
---|---|---|---|
What's up with all the 100 share buys? | csud1 | investorshub | 02/10/2023 7:19:31 PM |
znewcar1: $SRZN 46% v9,2M c1.13 f29,740M H1.18 ML.5313 gapNgo to hod | znewcar1 | investorshangout | 02/09/2023 9:09:44 PM |
Great day | Joelzee | investorshub | 02/09/2023 8:01:19 PM |
Buying .60s | BEIJING BILL | investorshub | 12/28/2022 6:43:12 PM |
sexy dilution lol>https://twitter.com/ThePberg/status/1602077645516472320/photo/1 | 81vette | investorshub | 12/15/2022 5:06:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Targeted protein degradation (TPD * ) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific a...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1...
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen...